PLK1 and precursor B-cell acute lymphoblastic leukemia: When Plk1-targeting siRNNs were applied to primary blood and bone marrow mononuclear cells from eight pediatric B-ALL patients, cultured ex vivo, Plk1 knockdown was detected in seven of the treated patient samples, independently of genetics or blood/bone marrow origin.